What is the prognosis and safety of immunotherapy treatment for elderly patients aged 80 with SM-CMML (systemic mastocytosis with CMML) and CMML-1?
SM-CMML is a rare and complex overlap condition, and treatment decisions for someone aged 80 require very careful consideration. General prognosis for CMML varies widely based Show Full Answer
What is the prognosis and safety of immunotherapy treatment for elderly patients aged 80 with SM-CMML (systemic mastocytosis with CMML) and CMML-1?
SM-CMML is a rare and complex overlap condition, and treatment decisions for someone aged 80 require very careful consideration. General prognosis for CMML varies widely based on individual factors, including:
- Age and overall health
- Blood cell counts
- Genetic mutations present
- Percentage of blasts in blood and bone marrow
- CMML subtype (CMML-1 generally has a better outlook than CMML-2)
For the lowest-risk CMML patients, survival can reach around 8 years, while higher-risk patients may have a shorter outlook of around 16 months. Your specialist is best placed to give a personalized prognosis. Regarding treatment at age 80, a bone marrow transplant — the only potential cure for CMML — is generally only considered for younger, healthier patients, so it may not be a realistic option here.
For SM-CMML specifically, targeted therapies are often explored, such as midostaurin (Rydapt), which blocks enzymes that leukemic cells use to grow. Other targeted therapies and chemotherapy options may also be considered depending on genetic mutations present.
For an 80-year-old, supportive care is often a central part of the treatment plan, focusing on:
- Managing symptoms
- Blood transfusions for low blood cell counts
- Growth factors to encourage new blood cell production
Clinical trials may also be worth discussing with a hematologist/oncologist, as they can provide access to newer therapies. Given the complexity of SM-CMML and the considerations around age, a specialist consultation is strongly recommended to weigh the risks and benefits of any treatment approach.
May 12
Join
Your Privacy Choices
